CYTK250516C80000
- 0.45
- 0.000.00%
Cytokinetics Newsroom
Morgan Stanley Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $65
Cytokinetics Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $53 to $107
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
Cytokinetics Is Maintained at Outperform by RBC Capital
Cytokinetics Price Target Cut to $80.00/Share From $86.00 by Citigroup
Cytokinetics Analyst Ratings
RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Cuts Target Price to $45
Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $80
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics: Hold Rating Amid FDA Delays and Commercial Uncertainties
Strategic Opportunity and Management Confidence Underpin Buy Rating for Cytokinetics Despite FDA Delay
Evercore ISI Remains a Buy on Cytokinetics (CYTK)
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Stifel Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $87
JMP Securities Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $78
Cytokinetics Is Maintained at Neutral by UBS
UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41
Cytokinetics Analyst Ratings